MATERNAL SERUM BIOCHEMICAL MARKERS PP13, PAPP-A, PlGF AND ADAM12 @ 11-13+6 WEEKS’ GESTATION AND ADVERSE PREGNANCY OUTCOMES by Matwejew, Elisabeth
1 
 
 
 
Department of Gynecology and Obstetrics 
(Director: Prof. Dr. med. Dr. hc. Walter Jonat, FRCOG) 
Christian-Albrechts-University at Kiel 
 
 
 
 
MATERNAL SERUM BIOCHEMICAL MARKERS 
PP13, PAPP-A, PlGF AND ADAM12 
@ 11-13
+6
 WEEKS’ GESTATION 
AND ADVERSE PREGNANCY OUTCOMES 
 
 
 
 
 
Inaugural dissertation to 
obtain the title of a Medical Doctor at 
the Medical Faculty of the 
Christian-Albrechts-University at Kiel 
 
 
submitted by 
Elisabeth Matwejew 
from Novosibirsk, Russia 
 
 
 
Kiel 2010 
2 
 
 
 
 
 
 
 
 
1st Assessor: 
Univ.-Prof Dr. med. C.S. v. Kaisenberg, MHH 
(CAU) 
2nd Assessor: Prof. Dr. rer. nat. N. Arnold 
3rd Assesor: Prof. Dr. med. C. Mundhenke, MA 
date of oral examination: 07.03.2012 
accepted to be printed, Kiel March 2012 
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
to my family 
and  
Alwis Cramer 
 
 
 
 
4 
 
Contents 
 
 
Contents .............................................................................................................................. 4 
1. Introduction ...................................................................................................................... 5 
2. Methods ......................................................................................................................... 10 
2.1 Study population....................................................................................................... 10 
2.1.1 Inclusion criteria ................................................................................................. 12 
2.1.2 Exclusion criteria ................................................................................................ 12 
2.3 Pre-analytical sample processing ............................................................................. 12 
2.4. Sample analysis ...................................................................................................... 13 
2.4.1 PP13 .................................................................................................................. 13 
2.4.2 PAPP-A ............................................................................................................. 14 
2.4.3 PlGF .................................................................................................................. 14 
2.4.4 ADAM12 ............................................................................................................ 14 
2.5 Statistics ................................................................................................................... 15 
2.5.1 PP13 .................................................................................................................. 15 
2.5.2 PAPP-A ............................................................................................................. 15 
2.5.3 PlGF .................................................................................................................. 15 
2.5.4 ADAM12 ............................................................................................................ 16 
3. Results ........................................................................................................................... 17 
3.1 PP13 ........................................................................................................................ 17 
3.2 PAPP-A .................................................................................................................... 20 
3.3 PlGF ......................................................................................................................... 22 
3.4 ADAM12 ................................................................................................................... 25 
4. Discussion ..................................................................................................................... 29 
5. Summary ....................................................................................................................... 37 
6. References .................................................................................................................... 39 
7. Acknowledgements ........................................................................................................ 47 
8. Curriculum Vitae ............................................................................................................ 48 
 
5 
 
1. Introduction 
Abnormal placentation can lead to adverse pregnancy outcomes such as small for 
gestational age (SGA), pre-eclampsia (PE) and hemolysis, elevated liver enzymes and low 
platelets (HELLP) syndrome, contributing to fetal and maternal morbidity and mortality. PE 
affects 3-5% of all pregnancies (Roberts and Cooper, 2001), and in its most severe form is 
also associated with SGA and requires induced early delivery. HELLP is a multisystemic 
disease severely affecting both the mother and the fetus which can be found in 0.17- 
0.85% of all pregnancies and appearing in 20% of severe pre-eclamptic cases. The criteria 
for the diagnosis of the condition are focused on markers for hemolysis, liver enzymes and 
thrombocytopenia (Mihu et al., 2007; Sibai and Ramadan, 1993). 
There are currently no effective preventive therapies for these disorders, and the only 
treatment for PE is induced delivery. Despite this, predictive markers would still be of value 
by identifying high risk pregnancies for future potential interventional trials as well as 
allowing additional monitoring of these pregnancies. 
More recently however, a metaanalysis of nine randomized controlled trials enclosing 1317 
women with PE has assessed the influence of gestational age at the time of introduction of 
Aspirin. Aspirin treatment beginning in early gestation was associated with a greater 
reduction in the incidence of preeclampsia than treatment beginning in late gestation: 
When Aspirin treatment started at 16 weeks’ gestation or below the RR was 0.48 (95% CI 
0.33 to 0.68), at 17-19 weeks’ 0.55 (95% CI 0.17 to 1.76) and at 20 weeks’ or higher 0.82 
(95% CI 0.62 to 1.09). When Aspirin treatment started especially before 16 weeks there 
was also a significant reduction in the incidence of severe preeclampsia (RR 0.10; 95% CI 
0.01 to 0.74), gestational hypertension (RR 0.31; 95% CI 0.13 to 0.78) and IUGR (RR 
0.51; 95% CI 0.28 to 0.92) (Bujold et al., 2009). 
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Ultrasound uterine artery Doppler provides information on the maternal blood flow to the 
placenta. Second trimester Doppler has been demonstrated to detect 45% - 55% of PE 
pregnancies (at 5% false positive rate (FPR)) increasing to 62% in combination with first 
trimester PAPP-A (Papageorghiou et al., 2004; Spencer et al., 2005). It is likely that first or 
second trimester biochemical markers such as PP13, PAPP-A, Inhibin and Activin A, in 
combination with Doppler and maternal biophysical parameters such as blood pressure or 
arterial stiffness, can increase the sensitivity (Spencer et al., 2005; Spencer et al., 2007a; 
Spencer et al., 2008c, Poon et al., 2010, Khalil et al., 2009a). Various biomarkers are 
under investigation for both PE and SGA. 
PP13 is a 32 KD dimer belonging to the galectin family of proteins (Than et al., 2004). It is 
expressed in placenta and it has been shown to play a role in trophoblast implantation, 
invasion and development of placenta during early stages of gestation (Than et al., 2004; 
Burger et al., 2004). Molecular studies on PP13 mRNA expression on trophoblasts of 
women with pre-eclamspia, have shown a down-regulation of the gene during first and 
third trimester (Sekizawa et al., 2008; Than et al., 2008). PP13 levels have been shown to 
be decreased in PE and SGA (Than et al., 2004; Chafetz et al., 2007; Gonen et al, 2008; 
Huppertz et al., 2008; Khalil et al,. 2009b; Nicolaides et al. 2006; Romero et al., 2008; 
Spencer et al., 2007a; Spencer et al., 2007b). In one published study, PP13 levels were 
not found to be significantly different in SGA pregnancies (Cowens et al., 2008). This is the 
first reported study using the new AutoDELFIA assay to measure PP13. 
PAPP-A belongs to the metzincin superfamily of zinc metalloproteases and is a regulator 
of IGF bioactivity in several systems (Lawrence et al., 1999). Through cleavage, PAPP-A 
causes a reduction in the affinity of insulin-like growth factor binding protein-4 (IGFBP-4) to 
IGF-I and II. Thus, PAPP-A has been proposed as a potential marker for dysfunctions of 
placental development such as SGA (Canini et al., 2008; Cowans et al., 2007; Spencer et 
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al., 2008a) and preeclampsia (Spencer et al., 2005; Pilas et al., 2007; Poon et al., 2009; 
Spencer et al., 2008b). 
Placenta growth factor (PlGF) is a dimeric glycoprotein member of the angiogenic vascular 
endothelial growth factor family, first isolated in 1991 and later found to be expressed 
predominantly by trophoblasts, and is able to cause endothelial cell proliferation, migration 
and activation (Maglione et al., 1991; Shore et al., 1997; Vuorela et al., 1997). In 
pregnancy, it is believed that PlGF and other angiogenic factors regulate trophoblast 
invasion of the maternal spiral arteries. Impaired trophoblast invasion leads to insufficient 
vascular remodelling of the spiral arteries than that which occurs in normal pregnancy. 
This leads to reduced perfusion of the placenta which is conceivably involved in the 
following adverse pregnancy outcomes: small for gestational age (SGA) pre-eclampsia 
(PE) and haemolysis elevated liver enzymes and low platelets (HELLP) (Weinstein 1982; 
Barker et al., 1993; Sibai and Ramadan 1993; Curtin and Weinstein 1999; Dekker and 
Sibai 2001; Roberts and Cooper 2001; Sibai et al., 2005; Mihu et al., 2007). Several 
studies of pregnancies affected by preeclampsia have indicated that PlGF levels are 
decreased in the first and second trimesters, as well as at the stage of clinical onset of the 
disease (Torry et al., 1998; Reuvekamp et al., 1999; Tjoa et al., 2001; Tidwell et al., 2001; 
Su et al., 2001; Taylor et al., 2003; Polliotti et al., 2003; Akolekar et al., 2008; Crispi et al., 
2008). Studies in the literature have shown inconsistent first trimester PlGF patterns in 
pregnancies resulting in SGA (Ong et al., 2001; Thadhani et al., 2004; Smith et al., 2007; 
Poon et al., 2008a; Erez et al., 2008). 
A-disintegrin-and-metalloprotease-12 (ADAM12) is a multidomain glycoprotein belonging 
to the reprolysin zinc metalloproteases family (Loechel et al., 1998). Alternative splicing 
produces a long and short form, and the short, circulating form has been shown to have 
cell adhesion property and proteolytic activity against binding proteins for insulin-like 
growth factor (Shi et al., 2000; Loechel et al., 2000). When first investigated in the 
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maternal circulation using a small series of samples on a quantitative enzyme-linked 
immunosorbent assay (ELISA), ADAM12 appeared to be an extremely promising marker 
for chromosomal aneuploides, with markedly reduced levels of the molecule in affected 
first trimester trisomies 21 and 18 maternal serum (Laigaard et al., 2003; Laigaard et al., 
2005a). Later studies, using a new DELFIA platform (PerkinElmer Life Sciences, Turku, 
Finland), supported these early results, placing the discriminatory power of ADAM12 
greatest prior to 10 weeks gestation (Laigaard et al., 2006a; Laigaard et al., 2006b; 
Spencer et al., 2007c; Spencer et al., 2008d,e). In the second trimester, ADAM12 levels 
were found to be increased in trisomy 21 pregnancies (Christiansen et al., 2007; Donalson 
et al., 2008). As a marker for adverse pregnancy outcomes, ADAM12 has been shown to 
be decreased in first trimester maternal serum of pregnancies which later went on to 
develop PE, and even further decreased in pregnancies which also resulted in a low birth 
weigh delivery (Laigaard et al., 2005b), or early, severe PE (Laigaard et al., 2005b; 
Spencer et al., 2008f). In addition, ADAM12 levels have been shown to decrease in 
pregnancies which resulted in growth restricted fetuses, supporting a role of ADAM12 in 
fetal growth (Cowans and Spencer, 2007; Pihl et al., 2008). However, a recent study has 
found no significant difference in first trimester maternal serum ADAM12 concentrations 
between controls and pregnancies resulting in PE (Poon et al., 2008b). In addition, 
although this study did find a decrease in first trimester maternal serum ADAM12 
concentrations in IUGR pregnancies, ADAM12 failed to emerge as a successful marker for 
this adverse outcome. To date, there are no published studies looking at ADAM12 and 
HELLP syndrome. The aim of the current study is to evaluate further the role of ADAM12 
as a potential marker of various adverse pregnancy conditions, including HELLP. 
 
In this case control study we aim to investigate first trimester maternal serum PP13, 
PAPP-A, PlGF and ADAM12 levels in a number of pregnancies which later developed one 
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or more of the following adverse outcomes: PE, IUGR, HELLP and GH. The rationale for 
the development of screening for PE at 11-13+6 weeks’ gestation is the much higher risk 
reduction if Aspirine treatment is started early. 
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2. Methods 
2.1 Study population 
This is a case-control study, part of a larger study supported by the European Union FP6 
(Pregenesys, Grant No. 037244) looking at first-trimester biochemical marker levels in 
pregnancies resulting in adverse outcomes. Maternal serum samples were collected at the 
University Hospital Schleswig-Holstein, Kiel, Germany, as part of an 11 +0 to 13 +6 weeks’ 
screening program for risk detection of fetal abnormalities. Gestational age was 
determined from the known date of the last menstrual period (LMP) and recalculated by 
ultrasonographic measurement of the crown-rump length (CRL) when exceeding more 
than 7 days’ difference to the last menstrual period. Simultaneously, the nuchal 
translucency measurement was taken. Additionally, maternal serum free -hCG and 
PAPP-A were measured using Kryptor (Brahms AG, Hennigsdorf, Germany). All 
components of the scan and the laboratory were licensed through the Fetal Medicine 
Foundation, London, UK. The parents were counselled immediately after the examination. 
Maternal demographic data (age, ethnic origin, smoking status, parity, height and weight) 
were recorded at the time of sampling and stored in a database. Informed consent was 
given for the use of excess serum, which was approved by the Ethical Committee of the 
Christian Albrecht University of Kiel, Kiel, Germany.  
Samples were collected between October 1998 and April 2008 and stored frozen until 
analysis (the median duration of storage was 5.17 years). Samples were generally stored 
at –70 ° C; however, some were stored intermittently at –20 ° C for up to 4 weeks in 
Germany and were shipped on ice by car to the UK in two batches (in 2004 and 2008) 
where they were stored at –20 ° C until testing.  
During the 10-year period of collection time, 3040 pregnancies were screened and 
delivered at this centre. From manual evaluation of labour ward books looking for written 
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evidence of PE, HELLP, GH and SGA, 56 abnormal pregnancies were identified and 
confirmed by accessing patient and birth records. Nine of these were excluded due to 
serum being unavailable. Many cases, in particular SGA, may have been missed when it 
was not recorded in the labour ward records, and logistically it was not feasible to search 
all birth records by birth weight. For each of the 47 cases, 10 chromosomally and 
structurally normal pregnancies which did not develop any adverse outcomes were 
selected for controls, matched for storage time and gestational age with the cases. 18 of 
these were excluded due to serum being unavailable. 
Figure 1 shows the number of controls and cases of all PE , all SGA and GH , as well as 
subsets created from these groups for HELLP , early and late PE and SGA (onset or 
delivery before or after 34 weeks), PE and SGA , PE only (without SGA nor HELLP) and 
SGA only (without PE).  
The samples were also measured for Placental Protein 13 (PP13), placental growth factor 
(PlGF) and ‘A disintegrin and metalloprotease-12’ (ADAM12) (Cowans et al., 2007; 2008; 
2010; Matwejew et al., 2010, Stamatopoulou et al., 2010). 
 
Figure 1. Case (and subsets) and control sample numbers. 
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2.1.1 Inclusion criteria 
All cases screened at the University of Schleswig-Holstein, Campus Kiel, Department of 
Obstetrics and Gynecology, Germany, collected between October 1998 and August 2008, 
from 11-13+6 weeks gestation, including both a measurement of nuchal translucency and 
first trimester serumbiochemistry. 
2.1.2 Exclusion criteria 
Multiple gestation, fetal structural or chromosomal abnormalities, fetal death, incomplete or 
missing screening at 11-13+6 weeks gestation. 
2.2 Adverse outcomes 
The definitions of PE and GH were those of the International Society for the Study of 
Hypertension in Pregnancy (Davey et al., 1988). GH is defined as diastolic blood pressure 
≥ 90 mmHg on two or more occasions, at least 4 hours apart, appearing after 20 weeks 
gestation in a previously normotensive woman, in the absence of significant proteinuria. 
PE is GH with ≥ 300 mg proteinuria in 24 hours, or two readings of at least ++ on dipstick 
analysis of midstream or catheter urine specimens in the absence of 24-hour collection 
availability. 
SGA was defined as a birth weight below the tenth percentile for the individual birth 
gestational day, using the Hadlock method and ViewPoint growth charts (Marsal et al., 
1996). 
2.3 Pre-analytical sample processing 
Samples were analyzed at the Department of Obstetrics and Gynecology, Christian 
Albrechts University at Kiel (free beta hCG and PAPP-A) and at the Department of Clinical 
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Biochemistry King George Hospital Barley Lane Goodmayes, London, UK (PP13, PlGF 
and ADAM12). 
Maternal venous blood was taken from the antecubital vein at the time of the nuchal scan 
(11-13+6 weeks). Monovette® test tubes (Neutral or Serum Z/7.5 ml, SARSTEDT, Sarstedt 
AG & Co, Nümbrecht, Germany) were used without any anticoagulants to obtain blood 
serum. Blood was spun within 30 minutes after it was taken and frozen (1.5ml Eppendorf 
tubes, no anticoagulants, Hamburg, Germany). All serum samples in each group were 
stored at -70°C in two to four aliquots. Samples were kept frozen at all times. Free beta 
hCG and PAPP-A was immediately analyzed at the time of screening. Samples were 
transferred to the Department of Clinical Biochemistry King George Hospital Barley Lane 
Goodmayes, London, UK, and kept frozen at all times. One to two aliquots were thawed, 
spun and the supernatant used for further analysis. Immediately before the final 
measurement samples were visually checked for hemolysis, hyperbilirubinemia and 
lipemia. All samples which were not perfectly clear were recorded. Biotin levels were not 
considered. 
2.4. Sample analysis 
2.4.1 PP13 
The samples were analysed for PP13 concentrations by automated time resolved 
fluoroimmunoassays using the AutoDelfia platform (PerkinElmer Life Science, Turku, 
Finland). Briefly, the method is a solid-phase, two-site fluorometric sandwich assay where 
monoclonal antibodies are directed against two separate antigenic determinants on PP13. 
The tracer antibody is europium-labelled, from which Eu-N3 chelate complexes form after 
addition of DELFIA inducer solution, which are counted by the AutoDelfia counter. PP13 
standards and samples were run in duplicate. Lab constructed serum controls were run in 
singleton at the start and end of each plate in all assays. 
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The analytical range of the assay is 14 to 861 pg/ml. Samples were run blind to outcome. 
 
2.4.2 PAPP-A 
PAPP-A concentrations were determined as part of the first trimester screening program 
patients had enrolled in, by Kryptor analyser (Brahms AG, Berlin) as described previously 
(Spencer et al., 1999). 
2.4.3 PlGF 
The samples were analysed for PlGF concentrations by an automated time resolved 
fluoroimmunoassay using the AutoDelfia platform (PerkinElmer Life Science, Turku, 
Finland). Briefly, the method is a solid-phase, two-site fluorometric sandwich assay where 
monoclonal antibodies are directed against two separate antigenic determinants on PlGF. 
The tracer antibody is europium-labelled, from which Eu-N3 chelate complexes form after 
addition of DELFIA inducer solution, which are measured by the AutoDelfia fluorescence 
reader. PlGF standards were run in duplicates while samples were run in singleton. Lab 
constructed serum controls were run in singleton at the start and end of each plate in all 
assays. 
The assay range is 10 to 999 pg/ml, and the samples were analysed without knowledge of 
the clinical outcome. 
2.4.4 ADAM12 
The samples were analysed for ADAM12 concentrations by an automated time resolved 
fluoroimmunoassay using the AutoDelfia platform (PerkinElmer Life Science, Turku, 
Finland). Briefly, the method is a solid-phase, two-site fluorometric sandwich assay where 
monoclonal antibodies are directed against two separate antigenic determinants on 
ADAM12. The tracer antibody is europium-labelled, from which Eu-N3 chelate complexes 
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form after addition of DELFIA inducer solution, which are measured by the AutoDelfia 
fluorescence reader. ADAM12 standards were run in duplicates while samples were run in 
singleton. Lab constructed serum controls were run in singleton at the start and end of 
each plate in all assays. 
The assay range is 15 to 1518 ng/ml, and the analytical sensitivity of the assay was 
typically >6ng/ml. The samples were analysed without knowledge of the clinical outcome. 
2.5 Statistics 
2.5.1 PP13 
PP13 levels were converted to multiples of the median (MoM) by dividing each individual 
result by the expected median marker of the control group at that gestational age (day). 
The control group was clustered into 10kg maternal weight bands, and the median log10 
PP13 MoM for each cluster was plotted against the median weight for each cluster to 
derive an equation to determine the weight corrected MoM, as outline previously (Spencer 
et al., 2003). The population was of the same ethnic origin, and PP13 levels were 
corrected for smoking status. 
2.5.2 PAPP-A 
PAPP-A MoMs were determined using ViewPoint at the time of screening, corrected for 
maternal weight and smoking status. Statistical significance was determined using Mann-
Whitney test for continuous variables, and 2 test for categorical variables. 
2.5.3 PlGF 
PlGF levels were converted to multiples of the median (MoM) by dividing each individual 
result by the expected median marker of the control group at that gestational age. The 
control group was clustered into 10kg maternal weight bands, and the median log10 PlGF 
MoM for each cluster was plotted against the median weight for each cluster to determine 
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if correction was required with PlGF (Spencer et al., 2003). The population was of the 
same ethnic origin (Caucasian), and PlGF levels were corrected for smoking status. 
Statistical significance was determined using Mann-Whitney test for continuous variables, 
and 2 test for categorical variables. 
2.5.4 ADAM12 
ADAM12 levels were converted to multiples of the median (MoM) by dividing each 
individual result by the expected median marker of the control group at that gestational 
age. To account for haemodilution, the control group was clustered into 10kg maternal 
weight bands, and the median log10 ADAM12 MoM for each cluster was plotted against 
the median weight for each cluster to derive an equation to determine the weight corrected 
MoM, as outline previously (Spencer et al., 2003). The population was of the same ethnic 
origin (Caucasian), and ADAM12 levels were corrected for smoking status. 
Statistical significance was determined using Mann-Whitney test for continuous variables, 
and 2 test for categorical variables. 
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3. Results 
3.1 PP13 
The demographic data for gestational age (weeks), maternal age (years), smoking, parity 
and maternal weigth (kg) for the controls, early onset and late onset PE, PE±SGA, HELLP 
Syndrome and GH are shown (Table 1). 
In the control group, PP13 concentrations increased slightly with gestational age, with 
median PP13 values for 11, 12 and 13 completed weeks being 53.5 pg/ml (n=78), 63.1 
pg/ml (n=258) and 65.7 pg/ml (n=112) respectively. There was enough control data to look 
at completed gestational days, and a weighted linear model was found to best fit this 
(r2=0.140, p<0.001), (Fig. 2). From this, the raw PP13 MoM was determined for each 
control and case. 
 
Figure 2. Relationship between PP13 concentration and gestational age. The line shown 
is a linear regression model: expected PP13 concentration = 5.045 × GA (weeks) - 1.196. 
18 
 
Table 1 Demographic data median variables in controls and each group. 
 
  Screening   Maternal   Fetal & delivery  
  
n 
GA (days) 
screening 
Maternal 
age (years) 
Smokers 
(%) 
Maternal 
weight (kg) 
Nulliparity 
(%) 
GA (days) 
delivery 
Fetal 
weight (g) 
APGAR 
Controls 452 88.00 33.64 10.0 68.00 44.4 279.0 3560.00 9.00 
All PE 33 87.00 34.10 12.1 90.60‡ 66.7* 263.0‡ 2950.00† 8.00‡ 
All SGA 15 87.00 31.63 13.3 76.45† 60.0 234.0‡ 1345.00† 8.00‡ 
GH 6 88.00 36.16 33.3 86.00† 16.7 277.0 3820.00 8.50 
HELLP 6 86.50 34.90 0.0 76.00 33.3 230.5† 1795.00† 8.50* 
Early PE 13 87.00 34.10 23.1 83.00‡ 46.2 231.0‡ 1555.00‡ 7.00‡ 
Late PE 20 87.00 34.01 5.0 94.00‡ 80.0† 270.0† 3285.00* 9.00‡ 
Early SGA 11 88.00 31.75 9.1 75.85* 54.5 224.0‡ 1270.00‡ 8.00‡ 
Late SGA 4 79.00* 31.15 25 85.15* 75.0 270.0 2432.50‡ 7.50‡ 
PE and SGA 7 82.00 34.10 14.3 93.00‡ 57.1 224.0‡ 990.00‡ 8.00‡ 
PE only 21 87.00 33.88 14.3 92.00‡ 76.2† 268.0‡ 3220.00† 8.00‡ 
SGA only 8 90.00 31.29* 12.5 69.00 62.5 255.5† 1562.50‡ 8.00‡ 
 
Symbols denote were a significant difference is found compared to the control group *p<0.05, †p<0.01, ‡p<0.001 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 3. Relationship between log10 PP13 MoM and maternal weight. The line 
shows a log-linear model, weighted by n, with the equation: corrected PP13 MoM = 
Raw MoM / 10 ^ ( -0.003 × Maternal Weight (kg) + 0.243). 
 
Log10 PP13 MoMs were found to be related to maternal weight (p<0.0001), shown 
with equation in Figure 3, and case and control pregnancies were corrected for 
maternal weight using this. 
Smokers in the control population were found to have a decreased PP13 median 
MoM of 0.57 vs non smokers MoM 1.03 (p<0.0001). To correct for this, smokers 
MoMs were divided by 0.57. 
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Table 2. Summary of PP13 research. 
Group GA (weeks) n MoM p-Value 
PE (alla or late onsetb) 
   Stamatopoulou et al., 2010a 
   Stamatopoulou et al., 2010b 
   Huppertz et al., 2008b 
   Chafetz et al., 2007a 
   Khalil et al., 2009ba 
   Romero et al., 2008a 
   Spencer et al., 2007ba 
   Spencer et al., 2007bb 
   Akolekar et al, 2009b 
 
11-14 
11-14 
11-15 
9-12 
11-14 
8-13 
11-14 
11-14 
11-14 
 
33 
20 
4 
47 
42 
50 
88 
44 
160 
 
1.08 
0.97 
0.15 
0.20 
0.40 
0.59 
0.69 
0.74 
0.96 
 
0.61 
0.82 
<0.05 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
N/S 
Early onset PE 
   Stamatopoulou et al., 2010 
   Nicolaides et al., 2006 
   Romero et al., 2008 
   Khalil et al., 2009b 
   Spencer et al. 2007b 
   Akolekar et al. 2009 
 
11-14 
11-14 
8-13 
11-14 
11-14 
11-14 
 
13 
10 
6 
14 
44 
48 
 
1.09 
0.07 
0.26 
0.30 
0.63 
0.83 
 
0.59 
<0.001 
<0.001 
<0.001 
<0.001 
<0.167 
SGA (<5th centilea, <10th centileb) 
   Stamatopoulou et al., 2010b 
   Chafetz et al., 2007a 
   Cowans et al., 2008b 
   Cowans et al., 2008a 
 
11-14 
9-12 
11-14 
11-14 
 
15 
45 
860 
488 
 
0.96 
0.60 
1.05 
1.06 
 
0.35 
<0.005 
0.93 
0.92 
MoMs are reported by each study for cases and p-value is from tests for 
independence (Mann-Whitney-Wilcoxon or Kruskal-Wallis) comparing cases to 
controls (MoM ≈ 1.0) as reported by each study. N/S=non significant 
 
3.2 PAPP-A 
PAPP-A MoMs were correct for gestational age, maternal weight and maternal 
smoking status at the point of screening. 
The corrected median PP13 and PAPP-A MoMs for the control group and each 
adverse outcome group are shown (Table 3). Significantly lower PAPP-A MoMs were 
found in the SGA groups both with (p<0.01) and without (p<0.001) PE. PAPP-A 
MoMs were also significantly decreased in the all PE group as well as the early PE 
group (p<0.05). We did not find any significant differences between PP13 levels in 
any group of cases compared to controls. 
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Table 3. Median MoMs for PP13 and PAPP-A for each group, comparison with 
controls using Mann-Whitney test. *p<0.05, †p<0.01, ‡p<0.001 
 
  PP13 PAPP-A 
 Median MoM p-value Median MoM p-value 
Controls 1.03  0.98  
All PE 1.08 0.61 0.76 <0.01 
All SGA 0.96 0.35 0.55 <0.001 
GH 0.93 0.49 1.01 0.93 
HELLP 0.91 0.35 0.71 <0.05 
early PE 1.09 0.59 0.72 <0.01 
late PE 0.97 0.82 0.82 0.08 
early SGA 0.92 0.29 0.54 <0.001 
late SGA 1.12 0.97 0.57 <0.05 
PE and SGA 1.09 0.80 0.55 <0.01 
PE only 1.21 0.19 0.89 0.20 
SGA only 0.91 0.30 0.54 <0.001 
 
The log10 PAPP-A and PP13 MoM are correlated with each other as well as free--
hCG and ADAM12, but not PlGF (Table 4). Markers free--hCG and PAPP-A were 
measured for fetal anomaly screening purposes, whereas PP13 and ADAM12 were 
measured in related studies (Matwejew et al., 2010; Cowans et al., 2010). 
 
Table 4. Correlation between log10 PAPP-A and PP13 and other first trimester 
maternal serum markers. 
 
Markers r-Value p-Value 
log PAPP-A vs log fßhCG 0.26 <0.0001 
log PAPP-A vs log PlGF -0.04 0.43 
log PAPP-A vs log ADAM12 0.15 <0.001 
log PAPP-A vs log PP13 0.13 <0.005 
log PP13 vs log fßhCG 0.16 <0.0005 
log PP13 vs log PlGF 0.09 0.06 
log PP13 vs log ADAM12 0.20 <0.0001 
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3.3 PlGF 
The demographic data for gestational age (weeks), maternal age (years), smoking, 
parity and maternal weigth (kg) for the controls, early onset and late onset PE, 
PE±SGA, HELLP Syndrome and GH are shown (Table 1). 
In the control group, PlGF concentrations increased with gestational age, and a 
lweighted regression model was found to best fit this (r2=0.718, p<0.001), (Figure 4), 
with equation. 
 
 
 
 
 
 
 
 
 
 
Figure 4. The PlGF concentration changes over gestational age are studied. The 
dots show actual data points, the line shows a linear regression model weighted by n 
with the equation: expected PlGF concentration = 1,58 x GA (days) – 53.62. 
 
From this, the raw PlGF MoM was worked out for each control and case PlGF 
concentration. PlGF MoMs were not found to be related to maternal weight 
(p=0.574), shown in Figure 5. Smokers in the control population were found to have 
an increased PlGF median MoM of 1.40 (p<0.0001). To correct for this, smokers 
MoMs were divided by 1.40. 
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Figure 5. The median PlGF MoM (plotted on log axis) and maternal weight plot. The 
line shows a regression model, weighted by n. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Scatter plots of PlGF concentrations by gestational age at screening. 
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The corrected median PlGF MoMs for the control group and each adverse outcome 
group are shown. Significantly lower PlGF MoMs were found in the HELLP, SGA, All 
PE, Early PE and PE – SGA groups (Table 5). 
 
Table 5. Median MoMs for each group, comparison with controls using Mann-
Whitney test. 
 
 N PlGF median MoM PlGF IQR  
Controls 452 0.99 0.33  
All PE 33 0.86 0.21 p<0.001 
All SGA 15 0.75 0.38 p<0.001 
HELLP 6 0.76 0.14 p<0.01 
GH 6 0.94 0.30  
PE and SGA 7 0.79 0.17  
PE no SGA/HELLP 21 0.92 0.21  
SGA no PE 8 0.51 0.25 p<0.001 
Early PE 13 0.78 0.19 p<0.01 
Late PE 20 0.89 0.22  
Early SGA 11 0.75 0.39 p<0.001 
Late SGA 4 0.73 0.47  
 
Bonferroni correction was not used due to its association with reduced statistical 
power and increase in type II errors. 
 
 
The log10 PlGF did not correlate with other pregnancy markers measured using the 
same sample (Table 6). The markers free--hCG and PAPP-A were measured for 
clinical purposes, whereas PP13 and ADAM12 were measured in related studies 
(Stamatopoulou et al., 2010; Matwejew et al., 2010). 
 
Table 6. Correlation between control group log10 PlGF MoM and other first trimester 
maternal serum log MoM. 
 
Markers r value 
log PlGF       vs. log fßhCG -0.038 
log PAPP-A  vs. log PlGF -0.037 
log PP13       vs. log PlGF   0.088 
log PlGF       vs. log ADAM12   0.014 
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3.4 ADAM12 
The demographic data for gestational age (weeks), maternal age (years), smoking, 
parity and maternal weigth (kg) for the controls, early onset and late onset PE, 
PE±SGA, HELLP Syndrome and GH are shown (Table 1). 
In one out of 452 controls, one had an undetectable level of ADAM12 and was 
therefore removed as an outlier. 
ADAM12 concentrations increased with gestational age, and a linear model was 
found to best fit this change (r2=0.652, p<0.001), (Figure 6) with equation. From this, 
the raw ADAM12 MoM was calculated for each ADAM12 concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Relationship between ADAM12 concentration and gestational age. The line 
shown is a linear regression model: expected ADAM12 concentration = 96.1 x 
gestational age (weeks) - 758.55. 
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Figure 8. Distribution of ADAM12 values as a function of gestational age in controls 
and all PE, all SGA, all HELLP and PE & SGA 
 
Raw ADAM12 MoMs were found to be inversely related to maternal weight (r2 = 
0.813, p<0.001), (Figure 8), and thus were corrected for using the following log-linear 
equation: 
corrected MoM = 2680.0)(0039.010  kgxWeight
MoM
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After these corrections, smokers in the control population were found to have a 
decreased ADAM12 median MoM of 0.88 (p=0.005). To correct for this, smokers 
maternal weight corrected MoMs were divided by 0.88. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Relationship between log10 ADAM12 concentration and maternal weight. 
The line shown is a log-linear model: corrected MoM = raw MoM/(10^(–0.0039 x 
maternal weight (kg) + 0.2680)). 
 
 
The first trimester median MoM ADAM12 values for control and each adverse 
outcome pregnancy group are shown (Table 7). Median MoM ADAM12 values were 
significantly higher than controls in HELLP and late PE group, and were not 
significantly different to controls in any other group studied. 
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Table 7. Median raw ADAM12 concentrations (ng/ml), median ADAM12 MoMs 
corrected for GA and median ADAM12 MoMs corrected for: GA, maternal weight and 
smoking, for each group. 
 
 Median 
ADAM12 
ng/ml 
Median 
ADAM12 
MoM 
Median 
ADAM12 
MoM corrected 
Controls 435.9 0.99 1.03 (0.41) 
All PE 422.0 0.97 1.16 (0.52)* 
All SGA 371.9 0.78 0.91 (0.52) 
GH 479.2 1.10 1.20 (0.17) 
HELLP 512.0 1.27 1.31 (0.56)* 
Early PE 417.0 0.97 1.16 (0.55) 
Late PE 432.5 0.94 1.17 (0.45) 
Early SGA 416.0 0.90 0.92 (0.40) 
Late SGA 249.2* 0.62 0.68 (0.28) 
PE and SGA 341.5* 0.71 0.92 (0.71) 
PE only 443.1 0.97 1.16 (0.4)* 
SGA only 406.7 0.90 0.92 (0.4) 
 
Median MoM comparison with controls using Mann-Whitney test. GA gestational age. 
*p<0.05. 
 
 
The correlation between log10 ADAM12 and other pregnancy markers measured 
using the same sample is shown (Table 8). Other markers were measured either in 
the clinic, as with free--hCG and PAPP-A or in related studies, as with PP13 and 
PlGF (Cowans et al., 2010; Stamatopoulou et al., 2010). ADAM12 was found to have 
a significant positive correlation with PAPP-A and PP13. 
 
Table 8. Correlation between log10 ADAM12 and other first trimester maternal serum 
markers MoMs 
 
Markers R value  
log ADAM12 vs. log fßhCG -0.012 *    p<0.05 
log ADAM12 vs. log PAPP-A 0.155‡ †   p<0.01 
log ADAM12 vs. log PP13 0.203‡ ‡   p<0.001 
log ADAM12 vs. log PlGF 0.014  
 
29 
 
4. Discussion 
In nulliparous women the number of total PE, late PE and PE-SGA cases was 
significantly more prevalent, when compared to control. This general observation 
supports the view that multiparity is protective of PE, possibly due to previous 
maternal exposure to the paternal antigen, as previously reported (Roberts et al., 
2001) (Table 1). 
Increased median maternal weight was also found in all PE groups, as previously 
reported (Dekker et al., 2001) (Table 1). 
Cigarette smoking reduced the levels of PP13 by about half and that of ADAM12, 
whereas PlGF levels were increased. 
 
This is the first study using the AutoDELFIA (PerkinElmer, Finland) platform to 
measure PP13, all previous studies were using the manual ELISA (DTL, Israel). We 
found a small increase in PP13 levels in the control pregnancies over the 11-14 week 
gestational period studied (Fig. 2), from which we derived a linear model to convert 
raw PP13 values into MoMs. Previous studies looking at this first trimester 
gestational age window are not all in agreement with regards to unaffected 
pregnancy PP13 levels. Some have also found a small positive correlation with 
gestational age (Chafetz et al., 2007; Romero et al., 2008; Cowans et al., 2008) while 
others have found no relationship (Huppertz et al., 2008; Nicolaides et al., 2006) and 
one reported a larger increase from 14.98pg/ml at 11 weeks increasing to 136.64 
pg/ml at 13 weeks (Khalil et al., 2009b). Overall, the median levels of PP13 detected 
using the ELISA in previous studies are roughly 2 fold higher than we found using the 
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AutoDELFIA, suggesting variation in the two platforms detection of PP13, or 
platform-to-platform calibration issues. In this study we found it necessary to correct 
for maternal weight and maternal smoking. Control smokers had a quite drastically 
reduced levels of PP13, with median MoM almost half that of control non-smokers. 
Reduction in smokers PP13 levels has been previously reported (Cowans et al., 
2007; Khalil et al., 2009b). 
The current study does not find any statistically significant relationship between 
corrected first trimester PP13 levels and the adverse pregnancy outcomes 
investigated. This is in contrast to the majority of published literature on first trimester 
PP13, where significantly lower levels of PP13 have been found in PE and SGA 
cases. Compared to control MoMs of approximately 1, first trimester median PP13 
MoMs from women who went on to develop PE have been reported as low as 0.15 
(p<0.05, n=4) (Huppertz et al., 2008), 0.2 (p<0.001, n=47) (Chafetz et al., 2007) 0.4 
(p<0.0001, n=42) (Khalil et al., 2009b) and 0.59 (p<0.001, n=50) (Romero et al., 
2008) and for early onset (<34 weeks) PE as low as 0.07 (p<0.001, n=10) (Nicolaides 
et al., 2006), 0.26 (p<0.001, n=6) (Romero et al., 2008) and 0.3 (p<0.0001, n=14) 
(Khalil et al., 2009b). In addition, a recent molecular study has found PP13 mRNA 
expression in 11 week syncytiotrophoblasts of women who developed PE to be lower 
than in normal pregnancies (Sekizawa et al., 2009). Women who went on to develop 
SGA have been reported in one study to have lower first trimester PP13 levels 
compared to controls, with a median MoM of 0.6 (p<0.005, n=42) (Chafetz et al., 
2007). However, another study found no significant differences in first trimester PP13 
levels in pregnancies which went on to deliver SGA (n=860) compared to controls 
(Cowans et al., 2008). 
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There are no previous studies looking at first trimester PP13 levels in pregnancies 
which later develop HELLP, however one group found third trimester PP13 maternal 
serum levels to be increased in PE and HELLP pregnancies, despite decreased 
PP13 expression in these tissues, due to an increase in membrane shedding of 
PP13 (Than et al., 2008). 
It is necessary to consider possible reasons for such contrasting results found in this 
study and a previous study (Cowans et al., 2008) compared to the consensus in the 
literature. As already mentioned, this study used the new AutoDELFIA platform, 
which gave median PP13 values for control pregnancies much lower than previously 
reported. Also this study was performed using samples with a mean storage time of 5 
years at -70oC, so stability of PP13 is a possible factor to consider, although controls 
were matched for storage time and gestation. 
Further studies using both the ELISA and AutoDELFIA platforms should be carried 
out to investigate the level of first trimester PP13 in pregnancies with adverse 
outcomes. Although the majority of studies suggest PP13 has the potential to be a 
good marker for PE, especially early onset PE, there is still a huge variation which 
needs to be addressed before the marker could realistically enter as a marker alone 
or in combination with other serum or ultrasound markers. 
 
In this study we found decreased levels of first trimester maternal serum PAPP-A in 
all PE, early PE and SGA (both with and without PE) (Tables 3, 4). This corroborates 
many previous studies which have found decreases in PAPP-A PE (5,9-12,34) and 
SGA (Canini et al., 2008; Spencer et al., 2008a, Kang et al., 2008). The low levels of 
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PAPP-A in these adverse pregnancy outcomes supports PAPP-A functioning as a 
IGFBP protease in the IGF pathway (Lawrence et al., 1999, Cowans et al., 2007). 
 
This is the first study to use the AutoDELFIA PlGF, rather than the R&D Systems 
PlGF ELISA platform. PlGF has been found to increase over the gestational window 
studied, as previously reported (Lambert-Messerlian and Canick, 2004; Akolekar et 
al., 2008). As found in the study of Akolekar et al (2008) we found a significant 
increase of PlGF in smokers but unlike this study, we were not confirm a relationship 
between PlGF and maternal weight nor PlGF and PAPP-A levels (Table 4, 6) 
(Akolekar et al., 2008). It is unlikely, that the different platforms, AutoDELFIA PlGF 
vs. the R&D Systems PlGF ELISA are the explanation for these differences. 
In pregnancies resulting in SGA, we found PlGF at 11-13+6 weeks to be significantly 
lower compared to control pregnancies (median PlGF MoM: SGA 0.503 vs. control 
0.987, p<0.001). Several similar studies have looked at PlGF in the first trimester in 
SGA pregnancies, however, there are inconsistencies in the literature. The first study 
to look at PlGF levels in first trimester serum of pregnancies that resulted in SGA with 
birth weight less than 5th centile actually found an increase in cases (median PlGF 
MoM: SGA 1.57 vs. control 0.98, p<0.001) (Ong et al., 2001). Later, a group reported 
no significant difference in PlGF levels between SGA pregnancies and controls after 
adjustment for gestational age in serum taken from weeks 7 to 12 (Thadhani et al., 
2004). Another study found increased first trimester PlGF levels were associated with 
a decreased risk of delivering an SGA infant (Smith et al., 2007). A further study, 
looking at the change in PlGF levels from first to second trimesters found a decrease 
in raw first trimester PlGF concentrations in 145 SGA pregnancies, not adjusted for 
gestational age (Erez et al., 2008). A smaller decrease than we found in median 
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PlGF MoMs has been reported in first trimester serum of SGA pregnancies with birth 
weight less than 5th centile (median PlGF MoM: SGA 0.900 vs. control 0.991, 
p<0.001) (Poon et al., 2008a). Our data support the idea that fetal growth, and 
ultimately birth weight, may be related to first trimester placental development. 
In this study we also found that at 11 to 13+6 weeks, median PlGF MoMs were 
significantly lower in some hypertensive pregnancy complications studied. There was 
no significant change in the levels of PlGF in gestational hypertension cases. Similar 
results have been previously presented (Akolekar et al., 2008). We found PlGF 
median MoMs to be decreased in HELLP, all PE, early PE and PE-SGA. PlGF has 
been previously found to be lower during the clinical stages of PE pregnancies (Torry 
et al., 1998; Reuvekamp et al., 1999). Various studies have also found PlGF levels to 
be significantly decreased in the second (Tjoa et al., 2001; Su et al., 2001; Taylor et 
al., 2003; Polliotti et al., 2003; Crispi et al., 2008) and first (Tidwell et al., 2001; 
Akolekar et al., 2008) trimesters in pregnancies destined for PE. In severe cases of 
PE, either early onset, or where both PE and SGA occur, PlGF levels are found to be 
further reduced (Tidwell et al., 2001; Taylor et al., 2003; Polliotti et al., 2003; Crispi et 
al., 2008). In contrast to these findings, there are a few studies undertaken prior to 20 
weeks of gestation where PlGF was found to be unaffected in pregnancies with pre-
eclampsia (Ong et al., 2001; Livingston et al., 2001; Lambert-Messerlian and Canick, 
2004). PlGF levels have also been found to be decreased in hydatidiform mole 
pregnancies (Koga et al., 2009) and normotensive but proteinuric pregnancies 
(Holston et al., 2009). 
We were able to detect a significant decrease in PlGF levels in HELLP syndrome, 
which agrees with previous findings on severe PE. In a previous study of expression 
of VEGF family members and receptors in situ and in vitro, PlGF was found to be 
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down regulated in cytotrophoblasts from severe PE and HELLP placental samples 
(Zhou et al., 2002). 
We have shown for PlGF to hold potential usefulness as a first trimester marker for 
SGA and some forms of PE. However, further studies should be carried out to 
attempt to reach a consensus on the usefulness of this marker both alone and in 
combination with ultrasound measurements, on the detection rate for these 
disorders. 
 
ADAM12 levels were found to steadily increase with gestational age over the window 
of time studied (Fig. 7). It was also found necessary to account for haemodilution in 
ADAM12 and to correct for the decreased levels of ADAM12 were found in smokers. 
All three of these aspects concur with previous studies (Laigaard et al., 2003; 
Makrydimas et al., 2006; Poon et al., 2008b; Spencer et al., 2008d,e). 
In this study we did not find any significant correlation between IUGR, all PE nor 
early PE first trimester ADAM12 levels and control levels. However, we did find that 
first trimester levels of ADAM12 are significantly raised in late PE and HELLP 
compared to control levels. This conflicts previous studies, which have shown levels 
of ADAM12 to be decreased or not altered at all in pregnancies with hypertensive 
disorders. In a recent study, Poon et al have shown no significant variation of first 
trimester ADAM12 levels in a cohort of 128 PE cases and 88 GH cases, and neither 
was a difference found when comparing early (<34weeks) and late (>34weeks) PE 
(P=0.871) (Poon et al., 2008). Lower levels of ADAM12 in the serum of PE women 
was observed in two studies (Laigaard et al., 2005b; Spencer et al., 2008f). In the 
study by Spencer, when the decreased levels of the molecule were combined with 
Pulsatility index (PI), there was an increase in the detection rate at 66% during the 
early first trimester screening. 
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Another study found increased levels of ADAM12 in the placental tissue and serum 
of second and third trimester women who developed PE (Gack et al., 2005). Gene 
expression of ADAM12 at late-second and third trimester showed an upregulation of 
its transcript among pre-eclamptic tissues. Further analysis of the molecule in 
maternal serum of the same gestational age, using western blotting, confirm the 
increase in patients diagnoses with PE. Spencer et al also found marginally 
increased levels of ADAM12 in the serum of second trimester women developing PE, 
which is consistent with the data by Gack (Gack et al., 2005; Spencer et al., 2008f). 
Similarly, the expression of the placental protein PAPP-A is increased in serum and 
placental tissue during the third trimester in pre-eclamptic pregnancies (Toop and 
Klopper, 1981; Bersinger et al., 2002, 2003; Gack et al., 2005; Deveci et al., 2009) 
and has also been shown to be raised in such pregnancies from 22-24 weeks 
(Spencer et al., 2006). In addition, the upregulation of the PAPP-A gene pappalysin 2 
(PAPPA2) has been found in 28 week HELLP pregnancy placentas (Buimer et al., 
2008). 
ADAM12 has a proteolytic role on insulin like growth factor binding protease-3 
(IGFBP-3) (Shi et al., 2000). It has been previously been shown that the levels of 
IGFBP-3 do not differ in pre-eclamptic and normotesensive women (Varma et al., 
1993; Hubinette et al., 2003). These findings support what we have found, in that 
ADAM12 levels are not altered in all PE and early PE groups. 
In this study, first trimester levels of ADAM12 were not found to be significantly 
different in IUGR cases and controls. This contradicts the findings of other studies, 
where ADAM12 levels have been found to be decreased in IUGR pregnancies 
(Cowans and Spencer, 2007; Poon et al., 2008b). ADAM12 is believed to be 
important in fetal growth, acting to increase levels of bioavailable IGFI and II, through 
proteolysis of IGFBP-3 (Cowans and Spencer, 2007). Therefore, lower levels of 
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ADAM12 in early pregnancy were postulated to result in decreased functionality of 
insulin-like growth factor pathways, leading to IUGR. However, the data found in the 
current study do not support this. 
With regard to the correlation of ADAM12, our data support findings from previous 
studies where ADAM12 was positively correlated with PAPP-A (Laigaard et al, 2003; 
Spencer and Cowans, 2007; Poon et al., 2008b). In addition, we have also shown 
ADAM12 to correlate with PP13. 
 
In this study we have to consider the stability of the samples. This study was 
performed in samples with a mean storage time of 5 years at -70°C. Although there 
are few studies on the stability of ADAM12 with time, Laigaard and colleagues 
excluded analysis of ADAM12 in samples beyond 4 years based on preliminary 
results they found (Laigaard et al., 2006a). Cowans and Spencer presented data 
which suggests that there is a significant loss of ADAM12 with time certainly at room 
temperature over a 3 day period with 50% loss, which confirmed previous findings of 
Laigaard et al (Laigaard et al., 2003;Cowans and Spencer, 2007). Further studies 
need to done on the long term stability of ADAM12 at lower storage temperatures. 
 
In conclusion, further studies of cases with PE are required to determine whether 
ADAM12 has a role to play in the earlier identification of pregnancies destined to 
develop PE or whether the previous studies showing reduced first trimester levels are 
merely a reflection of an associated growth restriction. Similarly in cases with HELLP 
we need more data to establish if the elevation seen in this study has any clinical 
value. 
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5. Summary 
 
The rationale for this study was to investigate the potential roles of maternal serum 
PP13, PAPP-A, PlGF and ADAM12 in the prediction of adverse pregnancy outcomes 
at 11-13+6 weeks gestation. These markers may be useful in establishing a follow up 
schedule for the pregnancy already at the end of the first trimester, or in the absence 
of risks to confirm normality. They may also be useful for the identification of 
pregnancies which may benefit from early Aspirin treatment. 
The current study does not find any statistically significant relationship between 
corrected first trimester PP13 levels and the adverse pregnancy outcomes 
investigated. This is in contrast to the majority of published literature on first trimester 
PP13, where significantly lower levels of PP13 have been found in PE and SGA 
cases. 
In this study we found decreased levels of first trimester maternal serum PAPP-A in 
all PE, early PE and SGA (both with and without PE), which corroborates many 
previous studies which have found decreases in PAPP-A and PE as well as SGA. 
In pregnancies resulting in SGA and in some hypertensive pregnancy complications, 
such as PE, early PE and PE-SGA as well as HELLP, we found PlGF at 11-13+6 
weeks to be significantly lower compared to control pregnancies. Our data support 
the idea that fetal growth, and ultimately birth weight, may be related to first trimester 
placental development. 
The present study did not find any significant correlation between IUGR, all PE nor 
early PE first trimester ADAM12 levels and control levels. However, we did find that 
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first trimester levels of ADAM12 are significantly raised in late PE and HELLP 
compared to control levels. 
One limitation of this study is the stability of the samples. This study was performed 
in samples with a mean storage time of 5 years at -70°C to -20°C. Although this was 
a case control study with the normal controls matched for gestation and storage time, 
this has to be considered. 
 
In conclusion this study shows, that maternal serum markers (PP13, PAPP-A, PlGF, 
ADAM12) at 11-13+6 wks of gestation in diseases based on abnormal placentation 
such as early and late onset PE, PE±SGA, HELLP Syndrome and GH are different 
from normal and may be useful in the subsequent management of the pregnancy. 
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